Spectrum Pharma (SPPI) Guides FY13 Below Views; Cites Change in FUSILEV Ordering Patterns

Go back to Spectrum Pharma (SPPI) Guides FY13 Below Views; Cites Change in FUSILEV Ordering Patterns

WallachBeth Capital Downgrades Spectrum Pharmaceuticals (SPPI) From Buy to Sell

March 13, 2013 8:47 AM EDT

WallachBeth Capital downgraded Spectrum Pharmaceuticals (NASDAQ: SPPI) from Buy to Sell with a price target of $5.50.

For an analyst ratings summary and ratings history on Spectrum Pharmaceuticals click here. For more ratings news on Spectrum... More

Spectrum (SPPI) Slammed on Resumption

March 12, 2013 5:12 PM EDT

Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) resumed trading. Shares are currently down over 35 percent in the after-hours session.... More

Spectrum Pharma (SPPI) trading halted for news

March 12, 2013 4:26 PM EDT

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading halted for news.... More